Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event

Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present a corporate overview at the 12th Annual LD Micro Main Event on Tuesday, December 10, 2019 at 4:40 pm PST in Bel-Air, CA.

In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor and Media Contact:Jenene Thomas Communications, LLC(833) [e-mail]

###